Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.16Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: -1.65%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong start to 2025 with significant revenue growth and improved profitability. A strategic acquisition and a robust financial position further highlight BioLife's positive trajectory. Potential challenges from industry headwinds were acknowledged, but their impact is not expected to be material in the near term.Company Guidance
In the first quarter of 2025, BioLife Solutions delivered a strong financial performance, with cell processing revenue increasing by 33% year-over-year to $21.6 million, contributing to a total revenue of $23.9 million, up 30% from the previous year. The company also reported an adjusted EBITDA margin of 24%. BioLife's core biopreservation media (BPM) product line remains a key driver, with 60% of BPM revenue coming from direct sales and 40% from distribution. Notably, 40% of total BPM revenue is derived from customers with approved commercial therapies. At the end of Q1, BioLife's BPM products were used in 17 approved therapies, with an estimated 70% usage in U.S. commercially sponsored CGT trials. The company reaffirmed its full-year revenue guidance of $95.5 million to $99 million, forecasting 16% to 20% growth. Adjusted gross margin is expected to remain in the mid-60% range.Strong Revenue Growth
Total revenue increased by 30% year-over-year, with cell processing revenue up 33%. This marks the sixth consecutive quarter of revenue growth.
Enhanced EBITDA Margin
Adjusted EBITDA margin expanded to 24%, up from 14% in the prior year, demonstrating strong operational efficiency.
Acquisition of PanTHERA CryoSolutions
The acquisition expands BioLife's biopreservation portfolio and enhances scientific capabilities, reinforcing its leadership in bioproduction consumables.
Strong Financial Position
BioLife ended the quarter with over $100 million in cash, providing a solid foundation for future growth.
Reaffirmed Financial Guidance
BioLife reaffirmed its full-year revenue guidance of $95.5 million to $99 million, with expected growth led by the cell processing platform.
---
BLFS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BLFS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $22.36 | $23.29 | +4.16% |
Mar 03, 2025 | $24.00 | $24.51 | +2.13% |
Nov 12, 2024 | $26.50 | $24.11 | -9.02% |
Aug 08, 2024 | $22.74 | $25.25 | +11.04% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does BioLife Solutions (BLFS) report earnings?
BioLife Solutions (BLFS) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is BioLife Solutions (BLFS) earnings time?
BioLife Solutions (BLFS) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BLFS EPS forecast?
BLFS EPS forecast for the fiscal quarter 2025 (Q2) is -0.03.
---